BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $14.67.

Several equities analysts have commented on the stock. JMP Securities raised their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 6th. Needham & Company LLC reissued a "buy" rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Barclays boosted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC boosted its stake in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 3,772 shares during the period. Signaturefd LLC boosted its position in shares of BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock worth $41,000 after buying an additional 5,599 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,322 shares during the period. nVerses Capital LLC purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at $63,000. Finally, Seven Eight Capital LP purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter worth about $57,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded up $0.11 on Friday, reaching $7.78. The company's stock had a trading volume of 1,573,346 shares, compared to its average volume of 2,394,392. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The company has a market capitalization of $1.61 billion, a P/E ratio of -12.75 and a beta of 1.89. The firm has a fifty day moving average of $7.76 and a two-hundred day moving average of $7.02.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same period in the previous year, the company posted ($0.19) EPS. The company's revenue for the quarter was up 35.1% compared to the same quarter last year. As a group, equities analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.